{"id":"NCT00494299","sponsor":"Bayer","briefTitle":"Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)","officialTitle":"Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2009-07","completion":"2010-11","firstPosted":"2007-06-29","resultsPosted":"2011-01-20","lastUpdate":"2013-12-20"},"enrollment":458,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sorafenib (Nexavar, BAY43-9006)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.","primaryOutcome":{"measure":"Time to Progression (TTP)","timeFrame":"From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months.","effectByArm":[{"arm":"Sorafenib (Nexavar, BAY43-9006)","deltaMin":164,"sd":null},{"arm":"Placebo","deltaMin":112,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":75,"countries":["Japan","South Korea"]},"refs":{"pmids":["21664811"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":229},"commonTop":["HAND-FOOT SKIN REACTION","RASH/DESQUAMATION","LIPASE","METABOLIC/LAB - OTHER (SPECIFY)","DIARRHEA"]}}